Ignite Creation Date:
2024-05-06 @ 2:15 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT02001545
Status:
COMPLETED
Last Update Posted:
2014-11-14
First Post:
2013-11-18
Brief Title:
REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients
Status:
COMPLETED
Status Verified Date:
2014-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RE-ACT
Brief Summary:
RE-ACT is a national multi-centre observational prospective longitudinal cohort study which will include patients hospitalized for ACS within 24 hours of symptom onset and who have a final diagnosis of ST-segment elevation myocardial infarction STEMI or non-ST-segment elevation myocardial infarction NSTEMI This study aims to describe the short-term at the end of the first month after index event antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None